

# Nanologica AB Receives Order Worth USD 180,000 from New Customer in China

**Nanologica has received an order for the company's silica-based purification media NLAB Saga® from a new customer in China. The customer is a large pharmaceutical manufacturer, and the order relates to evaluation of NLAB Saga® on a production scale.**

The order, which is worth USD 180,000, will be delivered during the second quarter.

*"This is a highly interesting customer for us as it is larger than some of the others we work with. Among other things, they manufacture GLP-1 analogues, which is where our products come in. We have been working with the customer for some time now and it is very positive that they want to move forward and evaluate our silica on a production scale. It shows that the work our team has done and is doing in China is paying off, and most importantly that our product is attractive and competitive. The fact that NLAB Saga® is of such high quality and has performed so well in the evaluations the customer has made so far is what makes them want to take the next step",* Nanologica's CEO Andreas Bhagwani comments.

## **For further information, please contact**

Johanna Johansson  
Director IR, Communications and Marketing  
johanna.johansson@nanologica.com  
+46 72 211 21 90

## **About Nanologica AB (publ)**

Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica's products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica's share (NICA) is listed for trading on Nasdaq Stockholm Main Market. For further information, please visit [www.nanologica.com](http://www.nanologica.com).

*This information is information that Nanologica AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-04-23 07:06 CEST.*

## **Attachments**

[Nanologica AB Receives Order Worth USD 180,000 from New Customer in China](#)